Egetis Therapeutics AB (EGTX.XSTO) Financials
All currency values in kr millions unless otherwise noted
Scroll
| Income Statement | TTM | DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | kr 66 | kr 62 | kr 46 | kr 58 | kr 23 | kr 38 |
| Cost of Revenue | kr 55 | kr 50 | kr 12 | kr 205 | kr 143 | kr 97 |
| Gross Profit | kr 11 | kr 12 | kr 35 | -kr 147 | -kr 120 | -kr 58 |
| Total Operating Expenses | kr 411 | kr 342 | kr 356 | kr 173 | kr 77 | kr 32 |
| Operating Income | -kr 400 | -kr 330 | -kr 322 | -kr 320 | -kr 197 | -kr 91 |
| Non-Operating | ||||||
| Net Interest Expense | -kr 19 | -kr 14 | -kr 18 | -kr 4 | -kr 0 | -kr 0 |
| Income Tax Expense | kr 0 | kr 0 | kr 0 | kr 0 | kr 0 | kr 0 |
| Net Income | ||||||
| Net Income | -kr 406 | -kr 343 | -kr 344 | -kr 327 | -kr 194 | -kr 105 |
| Per Share Data | ||||||
| Revenue Per Share | kr 0.14 | kr 0.17 | kr 0.15 | kr 0.22 | kr 0.12 | kr 0.21 |
| EPS (Basic) | -kr 0.90 | -kr 0.90 | -kr 1.10 | -kr 1.30 | -kr 1.00 | -kr 0.60 |
| EPS (Diluted) | -kr 0.90 | -kr 0.90 | -kr 1.10 | -kr 1.30 | -kr 1.00 | -kr 0.60 |
| Shares Outstanding | 456.1M | 368.2M | 306.5M | 256.8M | 194.2M | 179.9M |
Egetis Therapeutics AB (EGTX.XSTO) financials: revenue, profit and margins
Egetis Therapeutics AB (EGTX.XSTO) generated about SEK 66 million in revenue and -SEK 406 million in net income (a -613.5% net margin) over the trailing twelve months, growing at roughly 13.0% a year. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is Egetis Therapeutics AB's (EGTX.XSTO) revenue?+
Egetis Therapeutics AB generated about SEK 66 million in revenue over the trailing twelve months. Revenue has grown at roughly 13.0% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Egetis Therapeutics AB profitable?+
Egetis Therapeutics AB reported about -SEK 406 million in net loss over the trailing twelve months, a net margin of roughly -613.5%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Egetis Therapeutics AB's profit margins?+
Egetis Therapeutics AB runs a gross margin of about 16.8%, an operating margin of about -604.7%, a net margin of about -613.5%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Egetis Therapeutics AB growing?+
Egetis Therapeutics AB's revenue has compounded at roughly 13.0% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside EGTX.XSTO's margins and free cash flow. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.